2.33
price up icon17.09%   0.34
after-market Dopo l'orario di chiusura: 2.38 0.05 +2.15%
loading

Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie

pulisher
Nov 03, 2025

Will Acrivon Therapeutics Inc. stock benefit from green energy trendsPortfolio Return Summary & Low Risk Investment Opportunities - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Is Acrivon Therapeutics Inc. stock attractive for hedge fundsRecession Risk & Precise Buy Zone Tips - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech

Nov 03, 2025
pulisher
Nov 03, 2025

Is Acrivon Therapeutics Inc. stock a contrarian buyIPO Watch & Short-Term Swing Trade Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Is Acrivon Therapeutics Inc. stock supported by strong cash flows2025 Momentum Check & Weekly Sector Rotation Insights - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Will Acrivon Therapeutics Inc. stock split attract more investors2025 Trading Recap & Consistent Growth Stock Picks - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

What high frequency data says about Acrivon Therapeutics Inc.Weekly Trend Recap & AI Driven Price Predictions - newser.com

Nov 03, 2025
pulisher
Nov 02, 2025

Custom strategy builders for tracking Acrivon Therapeutics Inc.July 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Can Acrivon Therapeutics Inc. stock weather global recessionMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance

Nov 02, 2025
pulisher
Nov 02, 2025

Why Acrivon Therapeutics Inc. stock is recommended by analystsJuly 2025 Closing Moves & Community Verified Trade Signals - newser.com

Nov 02, 2025
pulisher
Oct 31, 2025

Will Acrivon Therapeutics Inc. rebound enough to break evenDip Buying & Free Reliable Trade Execution Plans - newser.com

Oct 31, 2025
pulisher
Oct 28, 2025

Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications - TipRanks

Oct 28, 2025
pulisher
Oct 27, 2025

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Oct 27, 2025
$37.30
price down icon 0.64%
$28.71
price up icon 0.35%
$101.57
price up icon 8.65%
$103.95
price up icon 0.04%
biotechnology ONC
$311.86
price up icon 0.44%
$186.23
price down icon 1.78%
Capitalizzazione:     |  Volume (24 ore):